Myriad Decision May Invalidate Many Patents
Analyzes the potential impact of the Myriad Genetics Supreme Court decision on the validity of issued patents in biotechnology and life sciences.
Featured Works
Publications & Cases
Selected whitepapers, articles, amicus briefs, and notable case contributions.
Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Genetics
Summarises the Supreme Court decision, outlines its impact, and provides practice tips for protecting nucleic acids, genes, cDNAs, and other biological molecules.
Amicus Brief — Commil USA v. Cisco (on behalf of BIO)
Authored amicus brief on behalf of the Biotechnology Industry Organization (BIO) in Commil USA v. Cisco before the United States Supreme Court.
Post-KSR Obviousness
Discusses changes in the patent law obviousness doctrine after KSR and provides strategy recommendations for protecting biotechnology inventions.
Patent Valuation after the America Invents Act and Stanford v. Roche
Covers patent valuation considerations following the AIA and the Supreme Court's decision in Stanford v. Roche.